

Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.
Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog	Status
Ethambutol 400mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Yes
Ethambutol/Isoniazid/Pyrazinamide/Rifampicin 275/75/400/150mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	No
Ethambutol/Isoniazid/Rifampicin 275/75/150mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	No
Isoniazid 100mg tablet	Yes	Yes	Yes	Yes	N/A	Ineligible for inclusion	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Isoniazid 300mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion
Isoniazid/Rifampicin 75/150mg tablet/capsule	Yes	Yes	Yes	Yes	Yes	N/A	Yes	Yes	Yes	No	Yes	No
Moxifloxacin 100mg dispersible tablet	N/A	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Ineligible for inclusion	Ineligible for inclusion	Yes	Ineligible for inclusion

DS-TB: Drug-Susceptible TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024

Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog	Status
Moxifloxacin 400mg tablet/capsule	Grey	Green	Green	Green	Green	Grey	Green	Green	Blue	Blue	Green	Yes
Pyrazinamide 400mg tablet/capsule	Green	Green	Green	Green	Green	Grey	Green	Green	Blue	Blue	Green	Yes
Pyrazinamide 500mg tablet/capsule	Green	Green	Green	Green	Green	Grey	Green	Green	Blue	Blue	Green	Yes
Rifabutin 150mg capsule	Green	Green	Green	Green	Green	Grey	Green	Green	Green	Red	Green	No
Rifampicin 150mg capsule	Green	Green	Green	Green	Green	Grey	Green	Green	Blue	Blue	Green	Yes
Rifampicin 300mg capsule	Green	Green	Green	Green	Green	Grey	Green	Green	Blue	Blue	Green	Yes
Rifapentine 150mg tablet	Grey	Green	Green	Green	Grey	Blue	Green	Green	Blue	Blue	Green	Ineligible for inclusion

Status
■ Yes
■ No
■ Ineligible for inclusion
■ N/A

DS-TB: Drug-Susceptible TB
 EML: Essential Medicines List
 EOI: Expression of Interest
 ERP: Expert Review Panel
 SRA: Stringent Regulatory Authority
 WHO PQ: World Health Organization Prequalification of Medicines Programme
 Version: November 2024

Adult Drug-Susceptible TB Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS, TB & Malaria**.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (DS-TB '22)	EML submitted	EML (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2024)	Global Fund ERP recommended	GDF Catalog	Status
Rifapentine 300mg	Grey	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green	Yes
Rifapentine/Isoniazid 300mg/300mg tablet	Grey	Green	Green	Green	Green	Green	Green	Green	Green	Red	Green	No
Rifapentine/Isoniazid/Moxifloxacin 300/75/100mg tablet	Grey	Green	Red	Red	Green	Green	Red	Blue	Green	Red	Blue	Ineligible for inclusion
Rifapentine/Isoniazid/Moxifloxacin/Pyrazinamide 300/75/100/375mg tablet	Grey	Green	Red	Red	Green	Green	Red	Blue	Green	Red	Blue	Ineligible for inclusion

DS-TB: Drug-Susceptible TB

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: November 2024